Immunotherapy: The Meta-Analyses. What have we Learned?

被引：27

作者：

Calderon, Moises A. ^{[1
]}

Boyle, Robert J. ^{[3
]}

Penagos, Martin ^{[2
]}

Sheikh, Aziz ^{[4
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Dept Allergy & Resp Med, Natl Heart & Lung Inst, Royal Brompton & Harefield Trust, London SW3 6LY, England

[2] St Thomas Hosp, Dept Paediat Allergy, London SE1 7EH, England

[3] Univ London Imperial Coll Sci Technol & Med, Dept Paediat, St Marys Hosp, London W2 1PG, England

[4] Univ Edinburgh, Allergy & Resp Res Grp, Ctr Populat Hlth Sci, Sch Med, Edinburgh EH8 9AG, Midlothian, Scotland

来源：

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA | 2011年 / 31卷 / 02期

关键词：

Specific allergen immunotherapy; Meta-analysis; Rhinitis; Asthma; SUBLINGUAL IMMUNOTHERAPY; ALLERGIC RHINITIS; RESPIRATORY ALLERGY; DOUBLE-BLIND; PEDIATRIC-PATIENTS; METAANALYSIS; EFFICACY; ASTHMA; DISEASES; CHILDREN;

D O I：

10.1016/j.iac.2011.02.002

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Meta-analysis is a powerful tool for evaluating the efficacy of a therapeutic intervention, and has clearly demonstrated that specific allergen immunotherapy (SIT) is effective for treating allergic rhinitis and asthma. Future research needs to focus on specifying the most effective forms of SIT for specific populations and allergens, using validated clinical outcomes, studying long-term outcomes (particularly the potential disease-modifying effect of immunotherapy), and assessing outcomes regarding health economics. The safety profile of SIT should be evaluated using international guidelines and terminology, and needs to include high-quality surveillance data.

引用

页码：159 / +

页数：16

共 50 条

[1] Meta-analyses of pain studies: What we have learned
Hauser, Winfried
Tolle, Thomas R.
[J]. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2015, 29 (01): : 131 - 146
[2] Meta-analysis. What have we learned?
Papakostidis, Costas
Giannoudis, Peter V.
[J]. INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED, 2023, 54 : S30 - S34
[3] What have we learned from network meta-analyses applied to critical care?
Baez-Pravia, Orville, V
Montes-Andujar, Lara
Menendez, Justo
Cardinal-Fernandez, Pablo
[J]. MINERVA ANESTESIOLOGICA, 2019, 85 (04) : 433 - 442
[4] Immunotherapy in colorectal cancer: What have we learned so far?
Sanchez-Castanon, Maria
Er, Tze-Kiong
Bujanda, Luis
Herreros-Villanueva, Marta
[J]. CLINICA CHIMICA ACTA, 2016, 460 : 78 - 87
[5] Immunotherapy Safety: What Have We Learned from Surveillance Surveys?
Kannan, Jennifer A.
Epstein, Tolly G.
[J]. CURRENT ALLERGY AND ASTHMA REPORTS, 2013, 13 (04) : 381 - 388
[6] Brain tumor immunotherapy: what have we learned so far?
Van Gool, Stefaan Willy
[J]. FRONTIERS IN ONCOLOGY, 2015, 5
[7] Immunotherapy Safety: What Have We Learned from Surveillance Surveys?
Jennifer A. Kannan
Tolly G. Epstein
[J]. Current Allergy and Asthma Reports, 2013, 13 : 381 - 388
[8] What have we learned?
Elshtain, JB
[J]. HIGHER LEARNING & CATHOLIC TRADITIONS, 2001, : 131 - 147
[9] What have we learned?
Rodgers, Peter
Collings, Andy
[J]. ELIFE, 2021, 10
[10] What Have We Learned?
Nason, John W.
[J]. JOURNAL OF HIGHER EDUCATION, 1944, 15 (06): : 287 - 298

← 1 2 3 4 5 →